Business Wire

MA-ICURE-PHARMACEUTICAL

16.11.2021 15:03:14 CET | Business Wire | Press release

Share
Icure Acquires Drug Product Approval for World’s First Donepezil Patch for Treating Dementia of the Alzheimer Type in Korea

Icure Pharmaceutical Inc. (KOSDAQ: 175250), a biopharmaceutical company in Korea, announced today that its donepezil patch, a treatment of Alzheimer’s-type dementia, received a drug product approval from the Ministry of Food and Drug Safety of Korea.

The drug product approval process took 7 months after it filed an application in April 2021. With the approval, Icure marks the first commercialization of the donepezil patch in the world.

Donepezil is a current typical treatment that has been widely prescribed for the longest period for Alzheimer’s disease patients in severity ranging from mild to moderate and severe ones among FDA-approved Alzheimer's treatments. Due to difficulty in the development of its formulations, donepezil has been commercialized for only oral administration to date.

With successful completion of a Phase III clinical trial for the first time in the world, the donepezil patch of Icure is expected to significantly improve the quality of life of patients with Alzheimer’s-type dementia and their caregivers by enhancing the convenience in its use from orally taking once daily to putting a patch on skin twice a week.

With nearly 400 mild and moderate dementia patients in Korea, Taiwan, Australia and Malaysia, Icure successfully conducted a Phase III clinical study for its donepezil patch. Specifically, the study demonstrated noninferiority compared to oral donepezil in Alzheimer's disease assessment scale cognitive subscale (ADAS-cog), a typical standard tool for evaluating abilities of memory, language, reorganization, action and orientation in patients with mild and moderate Alzheimer’s-type dementia.

“Based on outstanding efficacy and marketability of donepezil along with our technological prowess, we expect our donepezil patch will sufficiently take over the market of donepezil oral products as we have seen a high conversion rate of rivastigmine patches in the past,” said CEO YoungKweon Choi, Ph.D. of Icure, who led donepezil patch development. “We reported results of the Phase III clinical trial of donepezil patch at the Conference on Clinical Trials of Alzheimer’s Disease (CTAD) that was held on November 9~12, 2021 in Boston, Massachusetts.” He attended the CTAD Conference to present the results of the clinical study while making consultations on potential global transactions.

Now that its donepezil patch received FDA approval for Phase I clinical trial as an investigational new drug in April 2021, Icure will start to administer it to patients in the latter part of 2022. The company expects to begin in 2025 to provide the donepezil patch in the global market by reducing the period of clinical trials through the 505(b)2 clinical study track. Today, the global dementia treatments market is estimated to reach around USD 3 billion, and it is anticipated to increase to roughly USD 5 billion by 2024 as the world transforms into an aging society. Icure plans to expand the global business of transdermal drug delivery system (TDDS) as its production facilities in Wanju, Korea obtained the cGMP certification.

Starting with the donepezil patch, Icure diversifies pipelines by developing a variety of DDS-based incrementally modified drugs and new drugs. Following the donepezil patch, the company is developing a pramipexole patch that will be used for treating Parkinson’s disease. And Icure BNP, a subsidiary of Icure, is currently developing oral liraglutide peptide formulation from injectable liraglutide peptide product that is being used for treating diabetes and obesity while accelerating the development of microneedles and lipid-based nanoparticle (LNP) drugs through CuRsuS Bio and EBA BIO. In addition, Icure is also in the development of the world’s first oral peptide-based anticancer drug and a new drug based on PROTAC through oneCureGen and Dandi Cure, attracting attention on the potentiality of growing into a global pharmaceutical company by developing varied DDS-based new drugs.

For more information on Icure Pharmaceutical Inc., visit https://icure.co.kr .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Forrester Introduces AI Disruption Model To Assess AI’s Impact On Technology And Service Markets19.8.2026 11:00:00 CEST | Press release

With AI widening the divide across tech products and services, the model helps leaders identify the markets most likely to accelerate, transform, or face disruption According to Forrester’s (Nasdaq: FORR) AI Disruption Model, unveiled today, advancements in AI are disrupting technology markets at an unprecedented pace — enhancing the value of certain products and services while making others increasingly vulnerable to replacement. Two new reports, The Forrester AI Disruption Model: How AI Disrupts Or Accelerates Technology And Service Markets and The Forrester AI Disruption Model: Category Analysis, reveal that technology products and services that enable, secure, and govern AI are poised for significant growth due to organizations moving from experimentation to enterprise-scale deployment of AI applications and autonomous agents. In comparison, skills-based services will face disruption as AI assumes tasks that have traditionally depended on human expertise. Applied to 17 technology a

OKX Card Usage Surges Across Europe as Crypto Moves Into Everyday Spending19.8.2026 09:30:00 CEST | Press release

OKX Card purchase volume rises 280% year over year as European customers increasingly use digital assets for groceries, transport and other everyday expenses OKX, a leading global fintech company and crypto trading platform, today announced significant growth in everyday use of the OKX Card across Europe, with purchase volume increasing 280% year over year this summer and transactions rising 178%, as customers increasingly use the Card for routine spending including groceries, transport and fuel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819423550/en/ The OKX Card is designed to bridge the gap between holding digital assets and using them in everyday life, bringing earning, spending, and rewards together within the broader OKX ecosystem. The growth comes as crypto cards gain momentum across the wider payments industry. Industry-wide crypto card purchase volume reached a record $759 million in July, signalling that di

SAP strengthens its cloud infrastructure in Germany with BSI-approved Layer 1 encryption from Adva Network Security19.8.2026 09:00:00 CEST | Press release

News summary: SAP needed to secure connectivity between its German data centers to meet strict confidentiality, compliance and data control requirements BSI-approved Layer 1 encryption from Adva Network Security enables SAP to protect all data streams and future-proof its infrastructure against quantum threats Solution strengthens sovereign cloud foundations for government, critical infrastructure and regulated industries with high security and compliance needs Adva Network Security, an Adtran company, today announced that SAP is harnessing its Layer 1 encryption technology to secure connectivity between its data centers in Walldorf and St. Leon-Rot, Germany. The solution secures data directly at the optical transmission layer and is approved by the Federal Office for Information Security (BSI) for information classified up to “Verschlusssache – Nur für den Dienstgebrauch” (VS-NfD) – “For Official Use Only.” By strengthening the protection of data in transit, SAP is enhancing the secur

Qatar to Showcase Its Gaming Ambitions at Gamescom 202619.8.2026 09:00:00 CEST | Press release

Invest Qatar, the country’s Investment Promotion Agency, and Media City Qatar will participate at Gamescom 2026 through the “Qatar Pavilion”, highlighting Qatar’s growing role as a regional hub for game development, digital content and esports. Held annually in Cologne, Germany, Gamescom, a leading global event, brings together developers, publishers, investors and creators. Qatar’s participation reflects its focus on building a competitive, innovation-led ecosystem for gaming and interactive media. Mohammed Al Mulla, Head of Investment Development, Invest Qatar, said: “Gamescom provides a key platform to connect with global gaming leaders and highlight emerging opportunities across Qatar and the wider Middle East. We are focused on enabling companies to enter and scale in a high-growth market through a business environment designed for innovation and long-term success.” Dr. Fahad Abdulla Al Hajri, Business Development Manager, Media City Qatar, said: "Gaming is becoming one of the def

IFF to Webcast Fireside Chat at Barclays Global Consumer Conference on Sept. 1018.8.2026 22:15:00 CEST | Press release

IFF (NYSE: IFF) today announced that Chief Executive Officer Erik Fyrwald will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, Sept. 10, 2026 at 945 a.m. ET. Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818490253/en/

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye